Aktuelles und Veröffentlichungen
Aktuelles
Vigilant Biosciences Introduces the BeVigilant OraFusion System in Germany
Dusseldorf, Germany (Sept. 19, 2023) – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that assist in the early detection of oral cancer, announces the release of its breakthrough product, the BeVigilant OraFusion System, in...
The First Step to Enhancing Oral Cancer Detection: Recognizing Risk Factors and Symptoms
Oral cancer is a steadily growing threat that impacts millions of lives across the world, with nearly half of cases resulting in death.1 Current estimates report that one in 60 men and one in 141 women in the U.S. will develop oral cancer during their lifetimes.2...
The Consequences of a Missed Oral Cancer Diagnosis
A missed cancer diagnosis can be devastating. However, unlike other malignancies, oral cancer is more likely to progress unnoticed until life-threatening stages. This is mainly due to misdiagnosis of early-stage signs and symptoms. One case review found that, among 35...
The Limitations of Standard Oral Cancer Screening Methods
No matter the type of cancer, an early-stage diagnosis is paramount to ensuring patient survival. For many, the journey to a diagnosis begins with a screening. Cancer screening is not intended to make an official diagnosis; however, these assessments can achieve two...
Challenges in the Early Detection of Oral Cancer
Despite rapid innovation in cancer diagnostics and treatment, the oral cancer survival rate has yet to improve. Even after 40 years, the average survival rate has not surpassed 50% — an alarming figure spotlighting the need for more impactful diagnostic and treatment...
Wann sollte mit dem Screening auf Mundkrebs begonnen werden
Historically, oral cancer was thought to be an age-related malignancy; however, the growing prevalence of associated risk factors expands the demographic to younger age groups. This alarming shift brings to light the critical importance of proactive detection...
Vigilant Biosciences erhält von der FDA die „Breakthrough Device Designation“ für einen Point-of-Care-Test zur Unterstützung der Früherkennung von Mundkrebs
Vigilant Biosciences Receives Breakthrough Device Designation from FDA for Point-of-Care Test for Early Detection of Oral Cancer
Veröffentlichungen
Klinisches White Paper auf Anfrage erhältlich.